Core Insights - Scientific Industries Inc. has sold its Genie Division to Troemner, LLC for $9.6 million in cash, with potential earnouts of up to $1.5 million over the next year [1] - The company is shifting its focus towards AI-driven platforms in pharmacy automation and biomanufacturing, aiming to create long-term shareholder value [2] - The VIVID platform has deployed nearly 2,000 units, enhancing pharmacy automation and addressing pharmacist shortages [4] - The company is developing a machine learning pill library expected to launch in Q1 2026, which will improve accuracy and efficiency in pharmacy operations [4] - Scientific Bioprocessing's DOTS platform is set to revolutionize biomanufacturing by converting biological signals into machine-readable data [6][7] - The company has raised over $27 million since 2020 and plans to reinvest proceeds from the Genie division sale into scaling its core platforms [8] Company Strategy - The CEO emphasized the transformation from a legacy analog business to a digital infrastructure provider for the pharmacy and pharmaceutical industries [5][9] - The focus is on providing critical infrastructure to over 24,000 independent pharmacies in North America [5] - The company aims to position itself as a foundational technology provider for intelligent life science operations [9] Financial Overview - The financing secured on April 18, 2025, amounted to $1.5 million from existing investors through the sale of common stock and warrants [7] - The proceeds from the Genie division sale and warrant exercises will be reinvested into the Torbal Division and Scientific Bioprocessing platforms [7]